Discover ITT Inc.'s growth in revenue and profits, current valuation, and future outlook. Click for why a Hold rating is ...
Diversified operations rebound as MMM, ITT, and STRR capitalize on aerospace, defense, industrial growth, innovation, and ...
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer ...
(NYSE: ITT) today announced that its KONI business, a leading designer and manufacturer of advanced shock absorption ...
Advocates and lawmakers introduced the Accountability for For-Profit Colleges bill package on Oct. 15, 2025, during a press ...
Summit Therapeutics is aggressively pursuing U.S. approval for ivonescimab in NSCLC, despite lacking statistically ...
EDINBURG, Pa. (MyValleyTributes) – Phillips Charles Reed, 72, of Edinburg, passed away early Saturday morning, October 18, ...
Buying $100 In ITT: If an investor had bought $100 of ITT stock 5 years ago, it would be worth $267.35 today based on a price of $170.97 for ITT at the time of writing.
Theatre leaders have lamented slashed teacher training bursaries for creative subjects and figures revealing recruitment for ...
Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...
Zacks.com on MSN
Honeywell Gears Up to Report Q3 Earnings: Is a Beat in Store?
Detailed price information for Honeywell International Inc (HON-Q) from The Globe and Mail including charting and trades.
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback